Exosomes have become one of the most talked-about developments in regenerative aesthetics. They are being promoted for everything from improving skin quality and accelerating recovery after procedures to stimulating hair growth and supporting wound healing.
Yet despite all the excitement around them, exosomes remain one of the most misunderstood and regulatory-ambiguous treatment categories in the sector.
Research is developing rapidly, but much of the marketing has moved faster than the evidence. The regulatory landscape is complex, particularly regarding human-derived products, and many practitioners are unsure whether exosome treatments are covered by their medical malpractice insurance.
If you're considering adding exosomes to your clinic, here's what you need to know before making that decision.
Exosomes are tiny extracellular vesicles naturally released by cells. They act as biological messengers, carrying proteins, lipids and genetic material between cells to help regulate processes such as tissue repair, inflammation and cellular communication.
In regenerative medicine, researchers are interested in whether these signalling molecules can encourage damaged tissues to repair themselves more effectively.
Within aesthetics, exosome products are typically used alongside treatments such as microneedling, laser resurfacing or radiofrequency procedures, although some suppliers also promote injectable applications. Their intended purpose is to support healing, stimulate collagen production and improve overall skin quality.
Not all exosome products are the same, however. Some are derived from plants, while others originate from animal or human cells. The biological source has important implications for both the scientific evidence and the regulatory position.
The science behind exosomes is promising, but practitioners should be careful not to confuse promise with proof.
Much of the current research suggests exosomes may help improve wound healing, reduce inflammation and support collagen production. Early clinical studies have also reported encouraging improvements in skin quality and photoageing, particularly when exosomes are used alongside procedures such as radiofrequency microneedling or laser treatments. Recent comparative research has even suggested that certain exosome preparations may produce improvements comparable to platelet-rich plasma (PRP) in facial rejuvenation, although larger studies are still needed.
Hair restoration is another area attracting increasing attention. While the evidence base is expanding, most published studies remain relatively small, involve short follow-up periods and often assess different exosome preparations, making direct comparison difficult.
This highlights one of the biggest challenges facing practitioners.
The term "exosomes" describes a broad category of products rather than a single treatment. Manufacturing methods, biological sources, purification processes and quality controls vary considerably between manufacturers. Positive evidence for one product cannot automatically be applied to another.
That makes it particularly important to scrutinise supplier claims carefully. Marketing materials may reference published studies, but practitioners should check whether those studies relate to the specific product being supplied rather than exosome technology in general.
The regulatory picture surrounding exosomes continues to evolve and remains one of the most important considerations before introducing these treatments.
Human-derived exosome products in particular have attracted increased regulatory scrutiny.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) assesses exosome and extracellular vesicle products on a case-by-case basis. Products intended for therapeutic use, particularly those derived from human cells, are likely to fall within medicines legislation and may be classified as Advanced Therapy Medicinal Products (ATMPs), requiring an appropriate marketing authorisation before they can be commercially supplied.
At the time of writing, there are no MHRA-approved injectable exosome products with a UK marketing authorisation for aesthetic use, regardless of whether they are marketed as being derived from human, animal or plant sources.
One of the biggest misconceptions surrounding exosomes is that regulatory concerns only apply to injectable products. They do not. Human-derived exosome products raise regulatory issues regardless of whether they are injected, applied topically or used in conjunction with treatments such as microneedling. Practitioners should understand exactly how the product they intend to use is classified, what claims can legally be made about it and whether its use is compatible with both UK regulations and their medical malpractice insurance.
Investigations during the past year identified UK clinics offering treatments using human-derived exosome products, prompting renewed warnings for both practitioners and suppliers.
Plant and animal-derived products occupy a different regulatory position, but that should not be interpreted as meaning they are automatically supported by robust clinical evidence or suitable for every application.
Regardless of the source, practitioners should understand exactly how a product is classified, what claims can legally be made about it and whether the supplier can provide appropriate documentation regarding manufacturing, sterility, quality assurance and regulatory compliance.
A paper on the global Regulatory Landscape for Exosome-Based Therapeutics was published in 2025.
What does this mean for your insurance?
From an insurance perspective, regulatory compliance matters.
Using an unlicensed or non-compliant product may affect your medical malpractice insurance if a claim arises directly from that treatment. Even where a product has been supplied commercially, practitioners should never assume it is automatically covered.
Particular caution should be exercised with counterfeit or grey-market products.
Exosome treatments are not necessarily included within a general aesthetics policy. Before introducing any new treatment, check that it appears on your policy schedule and speak to your insurer if you are unsure.
Documentation also becomes particularly important.
Should a complaint or claim arise, comprehensive records help demonstrate that appropriate clinical judgement and informed consent formed part of the treatment process.
Before adding any exosome treatment to your clinic, ask yourself:
If you cannot confidently answer each of these questions, it may be sensible to pause before introducing the treatment.
Exosomes are one of the most exciting areas of regenerative medicine, and ongoing research may well establish an increasingly important role for them in aesthetic practice over the coming years.
But enthusiasm should always be matched by careful clinical judgement.
Practitioners who are likely to benefit most from this emerging treatment category are those who critically evaluate the evidence, understand the regulatory position, work only with reputable suppliers and confirm that appropriate insurance cover is in place before treating patients.
As with any developing area of aesthetic medicine, protecting your patients and protecting your practice should always go hand in hand.
To find out how Hamilton Fraser can support you in offering exosome treatments, get in touch with our specialist team today on 0800 63 43 881 or visit our website to get an online quote.
You can also visit the Hamilton Fraser content hub and check out these articles for more:
